- Home
- ARDX
ARDX
Ardelyx Inc.
as 11-21-2024 4:00pm EST
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.4B | IPO Year: | 2014 |
| Target Price: | $11.75 | AVG Volume (30 days): | 5.8M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.06 - $10.13 | Next Earning Date: | 10-31-2024 |
| Revenue: | $251,849,000 | Revenue Growth: | 87.57% |
| Revenue Growth (this year): | 167.24% | Revenue Growth (next year): | 18.93% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOTT DAVID M | ARDX | Director | Nov 13 '24 | Buy | $4.62 | 215,868 | $996,597.80 | 1,425,465 | |
| Rosenbaum David P. | ARDX | Chief Development Officer | Nov 6 '24 | Sell | $6.10 | 27,171 | $165,743.10 | 153,616 | |
| Rosenbaum David P. | ARDX | Chief Development Officer | Nov 4 '24 | Sell | $5.95 | 27,172 | $161,673.40 | 153,616 | |
| RAAB MICHAEL | ARDX | President & CEO | Oct 28 '24 | Sell | $5.91 | 25,000 | $147,740.00 | 1,210,108 | |
| Rosenbaum David P. | ARDX | Chief Development Officer | Sep 27 '24 | Sell | $6.92 | 49,564 | $342,982.88 | 153,616 | |
| RAAB MICHAEL | ARDX | President & CEO | Sep 26 '24 | Sell | $6.07 | 3,000 | $18,210.00 | 1,210,108 | |
| Rosenbaum David P. | ARDX | Chief Development Officer | Sep 13 '24 | Sell | $6.26 | 5,312 | $33,253.65 | 153,616 | |
| RAAB MICHAEL | ARDX | President & CEO | Sep 11 '24 | Sell | $5.61 | 35,000 | $196,399.00 | 1,210,108 | |
| RAAB MICHAEL | ARDX | President & CEO | Aug 27 '24 | Sell | $6.22 | 7,500 | $46,635.00 | 1,210,108 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Simply Wall St.
3 days ago
High Growth Tech Stocks To Explore In November 2024
Simply Wall St.
4 days ago
US Penny Stocks To Monitor In November 2024
Argus Research
7 days ago
Daily – Vickers Top Buyers & Sellers for 11/15/2024
MT Newswires
8 days ago
Ardelyx Insider Bought Shares Worth $996,598, According to a Recent SEC Filing
MT Newswires
11 days ago
HC Wainwright Downgrades Ardelyx to Neutral From Buy, Adjusts Price Target to $5.50 From $11.50
MT Newswires
14 days ago
Ardelyx Shares Fall After Federal Judge Dismisses Lawsuit Against CMS
GlobeNewswire
14 days ago
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.